Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal Academic Article in Scopus uri icon

abstract

  • © 2020 Asociación Mexicana de GastroenterologíaIntroduction: Inflammatory bowel disease (IBD) is a chronic and incurable entity. Therapy with anti-TNF-¿ agents was the first biologic therapy approved in Mexico for IBD. New biologic agents, such as vedolizumab and ustekinumab, have recently been added, as have small-molecule inhibitors. Aim: To update the biologic therapeutic approach to IBD in Mexico with new anti-TNF-¿ agents and novel biologics whose mechanisms of action induce and maintain remission of Crohn's disease and ulcerative colitis (UC). Materials and methods: Mexican specialists in the areas of gastroenterology and inflammatory bowel disease were summoned to participate. The consensus was divided into 3 modules, with 49 statements. The Delphi method was applied, sending the statements to all participants to be analyzed and edited, before the face-to-face meeting. During said meeting, the clinical studies were shown, emphasizing the level of clinical evidence, and the final discussion and voting round on the level of agreement of all the statements was conducted. Results: In this second Mexican consensus, recommendations are made for new anti-TNF-¿ agents, such as golimumab, new biologics with other mechanisms of action, such as vedolizumab and ustekinumab, as well as for the small-molecule inhibitor, tofacitinib. Conclusions: The updated recommendations focus on patient-reported outcomes, biologic therapy, small-molecule inhibitors, and the safety aspects of each of the drugs.

publication date

  • January 1, 2021